Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Lucian, DiPietro"'
Autor:
Stefanie S. Schalm, Erin O’Hearn, Kevin Wilson, Timothy P. LaBranche, Grace Silva, Zhuo Zhang, Lucian DiPietro, Neil Bifulco, Richard Woessner, Nicolas Stransky, Darshan Sappal, Robert Campbell, Riadh Lobbardi, Michael Palmer, Joseph Kim, Chaoyang Ye, Marion Dorsch, Christoph Lengauer, Timothy Guzi, Vivek Kadambi, Andrew Garner, Klaus P. Hoeflich
Publikováno v:
Gastro Hep Advances, Vol 2, Iss 3, Pp 307-321 (2023)
Background and Aims: Fibrolamellar carcinoma (FLC) is a rare, difficult-to-treat liver cancer primarily affecting pediatric and adolescent patients, and for which precision medicine approaches have historically not been possible. The DNAJB1-PRKACA ge
Externí odkaz:
https://doaj.org/article/2154c1b576ce47429fad42ed3d908a8f
Autor:
Ermira Pazolli, Randy Kipp, Alessandro Boezio, Hakan Gunaydin, Amanda Iskandar, Matthew Zubrowski, Bret Williams, Kelley Shortsleeves, Alexandre Larivee, Tom McLean, Klaus Michelsen, Hongtao Zeng, Jonathan LaRochelle, Joe Manna, Lucian DiPietro, Andre Lescarbeau, Mary Mader, Bindu Bennet, Jeremy Wilbur, Qi Wang, Levi Pierce, Iain Martin, James Watters, Pascal Fortin, Donald Bergstrom
Publikováno v:
Cancer Research. 82:P5-16
Inhibition of CDK4/6 combined with the estrogen receptor (ER) degrader fulvestrant significantly improves progression free survival and overall survival in advanced hormone receptor positive (HR+) breast cancer patients and is now the standard of car
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68ddad78553bc15ede0b650a5dff37d3
https://doi.org/10.1158/1538-7445.sabcs21-p5-16-10
https://doi.org/10.1158/1538-7445.sabcs21-p5-16-10
Autor:
Stefanie S. Schalm, Erin O’Hearn, Kevin Wilson, Timothy P. LaBranche, Grace Silva, Zhuo Zhang, Lucian DiPietro, Neil Bifulco, Richard Woessner, Nicolas Stransky, Darshan Sappal, Robert Campbell, Riadh Lobbardi, Michael Palmer, Joseph Kim, Chaoyang Ye, Marion Dorsch, Christoph Lengauer, Timothy Guzi, Vivek Kadambi, Andrew Garner, Klaus P. Hoeflich
Background & AimsFibrolamellar carcinoma (FLC) is a rare, difficult-to-treat liver cancer primarily affecting pediatric and adolescent patients, and for which precision medicine approaches have historically not been possible. The DNAJB1-PRKACA gene f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a2d4ab61e2b503458401ee32109d8f7
https://doi.org/10.1101/2022.01.31.477690
https://doi.org/10.1101/2022.01.31.477690
Autor:
Elena Garralda, Joseph L. Kim, Michael Palmer, Wei Hu, Kevin J. Wilson, Michael Sheets, Douglas Wilson, Marcia S. Brose, Vivek Subbiah, Christoph Lengauer, Justin F. Gainor, Sai-Hong Ignatius Ou, Michelle Maynard, Beni B. Wolf, Paul Fleming, Erica Evans, Jason D. Brubaker, Matthew H. Taylor, Rami Rahal, Mimi I. Hu, Lori J. Wirth, Lucian DiPietro, Stephen D. Miller, Qiongfang Cao, Timothy Guzi
Publikováno v:
Cancer Discovery. 8:836-849
The receptor tyrosine kinase rearranged during transfection (RET) is an oncogenic driver activated in multiple cancers, including non–small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and papillary thyroid cancer. No approved therapie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa86a49748bd34657ea36b58384cc476
https://doi.org/10.1158/2159-8290.cd-18-0338
https://doi.org/10.1158/2159-8290.cd-18-0338
Autor:
Ermira Pazolli, Randy Kipp, Alessandro Boezio, Hakan Gunaydin, Amanda Iskandar, Matthew Zubrowski, Bret Williams, Kelley Shortsleeves, Alexandre Larivee, Tom McLean, Klaus Michelsen, Hongtao Zeng, Jonathan LaRochelle, Joe Manna, Lucian DiPietro, Mary Mader, Bindu Bennet, Jeremy Wilbur, Qi Wang, Levi Pierce, Iain Martin, James Watters, Pascal Fortin, Donald Bergstrom
Publikováno v:
Molecular Cancer Therapeutics. 20:P251-P251
Phosphoinositide 3-kinase alpha (PI3Kα) is the most frequently mutated kinase in solid tumors. Traditionally, the development of PI3Kα inhibitors has focused on the active, or orthosteric site. The therapeutic index of orthosteric inhibitors is lim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::567d8dac909432d6fd3f2fd9a69edd1f
https://doi.org/10.1158/1535-7163.targ-21-p251
https://doi.org/10.1158/1535-7163.targ-21-p251
Autor:
Darshan S. Sappal, Vivek Kadambi, Riadh Lobbardi, Joseph L. Kim, Adam Shutes, Michael Palmer, Nicolas Stransky, Robert M. Campbell, Richard Woessner, Timothy LaBranche, Klaus P. Hoeflich, Neil Bifulco, Andrew P. Garner, Grace O. Silva, Erin O’Hearn, Kevin J. Wilson, Timothy J. Guzi, Stefanie Schalm, Marion Dorsch, Lucian DiPietro, Stephen D. Miller, Christoph Lengauer
Publikováno v:
Molecular Cancer Therapeutics. 18:B127-B127
Introduction: Fibrolamellar Carcinoma (FLC) is a rare primary liver malignancy, affecting children and young adults without chronic liver disease. FLC tumors are largely resistant to chemotherapy, making the identification of effective treatment opti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::49d5047a5f77900a009043aa6b75a1f6
https://doi.org/10.1158/1535-7163.targ-19-b127
https://doi.org/10.1158/1535-7163.targ-19-b127
Autor:
Vivek, Subbiah, Justin F, Gainor, Rami, Rahal, Jason D, Brubaker, Joseph L, Kim, Michelle, Maynard, Wei, Hu, Qiongfang, Cao, Michael P, Sheets, Douglas, Wilson, Kevin J, Wilson, Lucian, DiPietro, Paul, Fleming, Michael, Palmer, Mimi I, Hu, Lori, Wirth, Marcia S, Brose, Sai-Hong Ignatius, Ou, Matthew, Taylor, Elena, Garralda, Stephen, Miller, Beni, Wolf, Christoph, Lengauer, Timothy, Guzi, Erica K, Evans
Publikováno v:
Cancer discovery. 8(7)
The receptor tyrosine kinase rearranged during transfection (RET) is an oncogenic driver activated in multiple cancers, including non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and papillary thyroid cancer. No approved therapies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::eec07db5df6b7d30c144f60995259458
https://pubmed.ncbi.nlm.nih.gov/29967074
https://pubmed.ncbi.nlm.nih.gov/29967074
Autor:
Joseph L. Kim, Oleg Schmidt-Kittler, Yemarshet K. Gebreyohannes, Timothy Guzi, Kevin J. Wilson, Alison J. Davis, Alexandra K. Gardino, Adam Shutes, Christoph Lengauer, Lucian DiPietro, Stephen D. Miller, Brian L. Hodous, Yulian Zhang, Doug Wilson, Timothy LaBranche, Nicholas Lydon, Michael Heinrich, Nancy Kohl, Patrick Schöffski, Natasja Brooijmans, Agnieszka Wozniak, Erica Evans, Xing Julia Zhu, Daniel J. DeAngelo, Andy Boral, Beni B. Wolf
Publikováno v:
Science Translational Medicine. 9
Targeting oncogenic kinase drivers with small-molecule inhibitors can have marked therapeutic benefit, especially when administered to an appropriate genomically defined patient population. Cancer genomics and mechanistic studies have revealed that h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb6e3ad5639cb0b7a03fc75164a59dec
https://doi.org/10.1126/scitranslmed.aao1690
https://doi.org/10.1126/scitranslmed.aao1690
Autor:
Erica K, Evans, Alexandra K, Gardino, Joseph L, Kim, Brian L, Hodous, Adam, Shutes, Alison, Davis, Xing Julia, Zhu, Oleg, Schmidt-Kittler, Doug, Wilson, Kevin, Wilson, Lucian, DiPietro, Yulian, Zhang, Natasja, Brooijmans, Timothy P, LaBranche, Agnieszka, Wozniak, Yemarshet K, Gebreyohannes, Patrick, Schöffski, Michael C, Heinrich, Daniel J, DeAngelo, Stephen, Miller, Beni, Wolf, Nancy, Kohl, Timothy, Guzi, Nicholas, Lydon, Andy, Boral, Christoph, Lengauer
Publikováno v:
Science translational medicine. 9(414)
Targeting oncogenic kinase drivers with small-molecule inhibitors can have marked therapeutic benefit, especially when administered to an appropriate genomically defined patient population. Cancer genomics and mechanistic studies have revealed that h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::44c23e872b4ee8effe4e9b9a2cdce3de
https://pubmed.ncbi.nlm.nih.gov/30023395
https://pubmed.ncbi.nlm.nih.gov/30023395
Autor:
Timothy J. Guzi, Jason D. Brubaker, Beni B. Wolf, Christoph Lengauer, Douglas Wilson, Timothy LaBranche, Michelle Maynard, Lucian Dipietro, Joseph L. Kim, Wei Hu, Kevin J. Wilson, Michael Sheets, Erica Evans, Qiangfang Cao, Rami Rahal
Publikováno v:
Clinical Cancer Research. 24:B01-B01
Activating RET fusions have been observed in 1-2% of non-small cell lung adenocarcinomas (NSCLC). These tumors often occur in non-smokers and lack other driver mutations, similar to NSCLC driven by activation of the tyrosine kinases EGFR, ALK or ROS.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7582d1a9009506fec4f3ba67c77d8769
https://doi.org/10.1158/1557-3265.aacriaslc18-b01
https://doi.org/10.1158/1557-3265.aacriaslc18-b01